UKPDS 28: A randomized trial of efficacy of early addition of metformin in sulfonylurea-treated type 2 diabetes

UKPDS 28: A randomized trial of efficacy of early addition of metformin in sulfonylurea-treated type 2 diabetes

Detaylı Bibliyografya
Asıl Yazarlar:	Wright, A, Cull, C, Holman, R, Turner, R
Materyal Türü:	Journal article
Baskı/Yayın Bilgisi:	1998

Benzer Materyaller

UKPDS - 6-YEAR TRIAL OF SULFONYLUREA, INSULIN AND METFORMIN THERAPY IN TYPE-2 DIABETIC-PATIENTS WITH DIET FAILURE
Yazar:: Cull, C, ve diğerleri
Baskı/Yayın Bilgisi: (1995)

Hypoglycemia in Type 2 diabetic patients randomized to and maintained on monotherapy with diet, sulfonylurea, metformin, or insulin for 6 years from diagnosis: UKPDS73.
Yazar:: Wright, A, ve diğerleri
Baskı/Yayın Bilgisi: (2006)

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.
Yazar:: Turner, R, ve diğerleri
Baskı/Yayın Bilgisi: (1999)

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus - Progressive requirement for multiple therapies (UKPDS 49)
Yazar:: Turner, R, ve diğerleri
Baskı/Yayın Bilgisi: (1999)

Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57).
Yazar:: Wright, A, ve diğerleri
Baskı/Yayın Bilgisi: (2002)

Metformin as first choice in oral diabetes treatment: the UKPDS experience.
Yazar:: Holman, R
Baskı/Yayın Bilgisi: (2007)

Efficacy over six years of sulphonylurea plus insulin therapy in type 2 diabetic patients in the UKPDS
Yazar:: Cull, C, ve diğerleri
Baskı/Yayın Bilgisi: (2000)

Hypoglycaemia in patients with Type 2 diabetes in the UKPDS
Yazar:: Cull, C, ve diğerleri
Baskı/Yayın Bilgisi: (2001)

Ethnic differences in diabetic nephropathy - The UKPDS
Yazar:: Stevens, R, ve diğerleri
Baskı/Yayın Bilgisi: (1999)

UKPDS 26: Sulphonylurea failure in non-insulin-dependent diabetic patients over six years. UK Prospective Diabetes Study (UKPDS) Group.
Yazar:: Matthews, DR, ve diğerleri
Baskı/Yayın Bilgisi: (1998)

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)
Yazar:: Turner, R, ve diğerleri
Baskı/Yayın Bilgisi: (1998)

Changing aspirin use in patients with Type 2 diabetes in the UKPDS.
Yazar:: Cull, C, ve diğerleri
Baskı/Yayın Bilgisi: (2004)

Cost-effectiveness analysis of intensive blood-glucose control with metformin in overweight patients with type II diabetes (UKPDS No. 51).
Yazar:: Clarke, P, ve diğerleri
Baskı/Yayın Bilgisi: (2001)

UKPDS 26: Sulphonylurea failure in non-insulin-dependent diabetic patients over six years
Yazar:: Matthews, DR, ve diğerleri
Baskı/Yayın Bilgisi: (1998)

The UKPDS study on glycemic control and arterial hypertension in type II diabetes: objectives, structure and preliminary results
Yazar:: Levy, J, ve diğerleri
Baskı/Yayın Bilgisi: (1993)

[The UKPDS study on glycemic control and arterial hypertension in type II diabetes: objectives, structure and preliminary results]
Yazar:: Levy, J, ve diğerleri
Baskı/Yayın Bilgisi: (1993)

UK PROSPECTIVE DIABETES STUDY (UKPDS) .10. URINARY ALBUMIN EXCRETION OVER 3 YEARS IN DIET-TREATED TYPE-2, (NON-INSULIN-DEPENDENT) DIABETIC-PATIENTS, AND ASSOCIATION WITH HYPERTENSION, HYPERGLYCEMIA AND HYPERTRIGLYCERIDEMIA
Yazar:: Cull, C, ve diğerleri
Baskı/Yayın Bilgisi: (1993)

UKPDS: what was the question? UK Prospective Diabetes Study.
Yazar:: Turner, R, ve diğerleri
Baskı/Yayın Bilgisi: (1999)

Glycemic control continues to deteriorate after sulfonylureas are added to metformin among patients with type 2 diabetes.
Yazar:: Cook, M, ve diğerleri
Baskı/Yayın Bilgisi: (2005)

UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance.
Yazar:: Turner, R, ve diğerleri
Baskı/Yayın Bilgisi: (1991)

Plasma lipids and hypoglycaemic therapies over 6 years in Type 2 diabetic patients in the UKPDS
Yazar:: Cull, C, ve diğerleri
Baskı/Yayın Bilgisi: (1999)

Long-term efficacy of sulfonylureas: a United Kingdom Prospective Diabetes Study perspective.
Yazar:: Holman, R
Baskı/Yayın Bilgisi: (2006)

Additive effects of glycaemia and blood pressure exposure on risk of complications in type 2 diabetes: a prospective observational study (UKPDS 75).
Yazar:: Stratton, I, ve diğerleri
Baskı/Yayın Bilgisi: (2006)

Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study.
Yazar:: Adler, A, ve diğerleri
Baskı/Yayın Bilgisi: (2000)

United kingdom prospective diabetes study 24: A 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy
Yazar:: Wright, A, ve diğerleri
Baskı/Yayın Bilgisi: (1998)

Framingham equations underestimate cardiovascular risk compared with the UKPDS risk engine in people with Type 2 diabetes
Yazar:: Price, H, ve diğerleri
Baskı/Yayın Bilgisi: (2007)

COMPARISON OF TREATMENT OF MILD DIABETES WITH A BASAL INSULIN SUPPLEMENT OR SULFONYLUREA
Yazar:: Holman, R, ve diğerleri
Baskı/Yayın Bilgisi: (1977)

Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64).
Yazar:: Adler, A, ve diğerleri
Baskı/Yayın Bilgisi: (2003)

Low branched chain amino acids and tyrosine in Thai patients with type 2 diabetes mellitus treated with metformin and metformin-sulfonylurea combination therapies
Yazar:: Sriboonvorakul, N, ve diğerleri
Baskı/Yayın Bilgisi: (2021)

The Fasting Hyperglycaemia Study: III. Randomized controlled trial of sulfonylurea therapy in subjects with increased but not diabetic fasting plasma glucose.
Yazar:: Karunakaran, S, ve diğerleri
Baskı/Yayın Bilgisi: (1997)

The impact of diabetes-related complications on healthcare costs: new results from the UKPDS (UKPDS 84).
Yazar:: Alva, M, ve diğerleri
Baskı/Yayın Bilgisi: (2014)

Glucose control in UKPDS type 2 diabetic patients with and without autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase.
Yazar:: Mehta, Z, ve diğerleri
Baskı/Yayın Bilgisi: (1999)

Risk factors for neuropathy in UKPDS
Yazar:: Stratton, I, ve diğerleri
Baskı/Yayın Bilgisi: (2004)

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study.
Yazar:: Stratton, I, ve diğerleri
Baskı/Yayın Bilgisi: (2000)

Islet autoantibodies in clinically diagnosed type 2 diabetes: prevalence and relationship with metabolic control (UKPDS 70).
Yazar:: Davis, T, ve diğerleri
Baskı/Yayın Bilgisi: (2005)

Relationship between ethnicity and glycemic control, lipid profiles, and blood pressure during the first 9 years of type 2 diabetes: U.K. Prospective Diabetes Study (UKPDS 55).
Yazar:: Davis, T, ve diğerleri
Baskı/Yayın Bilgisi: (2001)

UKPDS 18: Estimated dietary intake in type 2 diabetic patients randomly allocated to diet, sulphonylurea or insulin therapy
Yazar:: Eeley, E, ve diğerleri
Baskı/Yayın Bilgisi: (1996)

One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes.
Yazar:: Hanefeld, M, ve diğerleri
Baskı/Yayın Bilgisi: (2004)

IA-2 antibody prevalence and risk assessment of early insulin requirement in subjects presenting with type 2 diabetes (UKPDS 71).
Yazar:: Bottazzo, G, ve diğerleri
Baskı/Yayın Bilgisi: (2005)

RANDOMIZED CONTROLLED TRIAL OF SULFONYLUREA THERAPY IN 227 SUBJECTS WITH PERSISTENT FASTING HYPERGLYCEMIA
Yazar:: Karunakaran, S, ve diğerleri
Baskı/Yayın Bilgisi: (1995)